Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Lexiva Boosted with 100 mg. of Norvir
Sep 2, 2007

Two studies recently reviewed at IAS 2007 indicated positive results for the use of Lexiva boosted with 100 mg. of Norvir instead of the standard 200 mg. (http://www.aidsmeds.com/articles/1667_12670.shtml). Are you boosting Lexiva with 100 or 200 mg. of Norvir in your practice? Thanks.

Response from Dr. Young

Thank you for your post.

Provided that we're talking about patients with wild type, drug susceptible virus (confirmed by genotypic or phenotypic testing), then we've largely switched to using a single 100 mg ritonavir (Norvir) to boost fosamprenavir (Lexiva, Telzir). The resulting 3-pill, once-daily PI regimen (component) is very well tolerated and doesn't have the dietary restriction of the other commonly prescribed first-line PI, atazanavir (Reyataz). BY



Previous
Switching Meds or Holiday? PLEASE HELP!
Next
Follow Up on Switching meds or drug holiday

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement